Here’s a roundup of the latest dealflow and investment news:
- PneumRx nets $33 million
PneumRx Inc. raised $33 million in working capital commitments, according to the company. The oversubscribed round was led by Europe-based venture capital firms Forbion Capital Partners and Endeavour Vision. Previous investors Adams Street Partners, Telegraph Hill Partners, Alta Partners and Spray Venture Partners also supported the round. Silicon Valley Bank and Leader Ventures also provided financing. The funding is designed to support the Mountain View, Calif.-based medical device company’s RePneu lung volume reduction coil system and a pivotal clinical trial to intended to support a pre-market approval application, according to PneumRx.
- Neograft Technologies raises $3 million
Neograft Technologies Inc. raised $3 million from five unnamed investors in an equity-based round, according to an SEC filing. The Pittsburgh, Pa.-based company is developing a device called Angioshield "for delivery of controlled temporary structural support to veins intended for use as [arterial vein grafts]," according to the company’s website.
- Zeo pulls in 12.3 million
Zeo Inc. raised $12.3 million from a $15.4 million round, according to an SEC filing. The equity-based financing came from 13 unidentified investors. In August 2010 the Newton, Mass.-based sleep-monitoring company, formerly known as Axon Labs, raised $1 million in a debt-based round.
- Cambridge Heart announces exercise of options worth $752,000
Cambridge Heart Inc. (OTC:CAMH) announced that all investors in the Dec. 2009 Series D convertible preferred stock financing elected to exercise the outstanding short-term warrants. The exercise of the short-term warrants generated a total of $752,000 in proceeds, and resulted in the issuance of slightly more than 7 million shares of common stock, according to the Tewksbury, Mass.-based developer of non-invasive diagnostic tests for cardiac disease.
- Augmenix drums up $3 million
Augmenix Inc. raised $3 million in the form of equity and debt from 22 unnamed investors, according to an SEC filing. The Waltham, Mass.-based company makes the SpaceOAR prostate-rectum separation hydrogel system intended to protect the body during radiotion oncology procedures.
- Iquum extracts $4 million from investors
Iquum Inc. raised $4 million from six unnamed investors in a debt and options-based round, according to an SEC filing. The Marlborough, Mass.-based biological sample testing technology developer is looking to raise another $1 million.
- NeuWave raises $5.6 million
Madison, Wis.-based NeuWave Medical Inc. raised $5.6 million of an $8 million round ahead of its sales efforts for a cancer treatment that recently won Food & Drug Administration 510(k) clearance. The equity and debt-based round was supported by 19 unidentified investors, according to SEC filings.